Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for ARDX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 149.01M
March 31, 2026 148.62M
December 31, 2025 166.95M
September 30, 2025 154.28M
June 30, 2025 139.53M
March 31, 2025 145.68M
December 31, 2024 173.29M
September 30, 2024 158.30M
June 30, 2024 146.99M
March 31, 2024 150.89M
December 31, 2023 166.82M
September 30, 2023 191.16M
June 30, 2023 123.16M
March 31, 2023 125.42M
December 31, 2022 98.33M
September 30, 2022 66.86M
June 30, 2022 53.04M
March 31, 2022 64.19M
December 31, 2021 82.62M
September 30, 2021 81.43M
June 30, 2021 117.57M
March 31, 2021 130.81M
December 31, 2020 126.11M
September 30, 2020 131.34M
June 30, 2020 146.35M
Date Value
March 31, 2020 167.76M
December 31, 2019 186.66M
September 30, 2019 49.16M
June 30, 2019 68.62M
March 31, 2019 91.84M
December 31, 2018 115.81M
September 30, 2018 141.45M
June 30, 2018 163.41M
March 31, 2018 128.98M
December 31, 2017 139.31M
September 30, 2017 126.64M
June 30, 2017 144.98M
March 31, 2017 167.68M
December 31, 2016 193.15M
September 30, 2016 222.89M
June 30, 2016 140.60M
March 31, 2016 167.75M
December 31, 2015 108.90M
September 30, 2015 125.13M
June 30, 2015 142.26M
March 31, 2015 58.00M
December 31, 2014 60.68M
September 30, 2014 63.30M
June 30, 2014 62.87M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
REGENXBIO, Inc. 71.76M
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M

Shareholders Equity (Quarterly) Related Metrics